The significantlyimproved median survival time, the 37% long term survivors, and the significantlylower tumor volume in the combined therapy (SG600-IL-24 and IFN-α) compared tothose of the single modality groups and controls suggests that these modalitiescomplement their anti-tumor activities. This evidence concerns the gene IFNA17 and neoplasm.